Mene Pangalos, AstraZeneca R&D chief (AstraZeneca via YouTube)
The FDA hands Farxiga 'breakthrough' status in CKD, clearing path for AstraZeneca's much-touted therapy
AstraZeneca has been promising big things on Farxiga in kidney disease since March, when they stopped a Phase III trial over what they deemed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
